Alto Neuroscience names Karuna Therapeutics founder Andrew Miller to board

Alto Neuroscience, Inc.
Karuna Therapeutics

Alto Neuroscience, Inc.

ANRO

0.00

Karuna Therapeutics

KRTX

0.00
  • Alto Neuroscience named Andrew Miller to its board, effective May 27, 2026.
  • Miller founded Karuna Therapeutics. He led R&D. He also served as CEO and COO. Karuna sold to Bristol Myers Squibb for $14 billion in 2024.
  • He was lead inventor of KarXT, now marketed by Bristol Myers Squibb as COBENFY for schizophrenia.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605280803BIZWIRE_USPR_____20260528_BW661041) on May 28, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.